Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Wuhan Bowo Biological Technology

Request full access

Developing and marketing high-quality human vaccines

Wuhan, China

About Wuhan Bowo Biological Technology

Wuhan Bowo Biological Technology Co., Ltd. (BravoVax) is a biopharmaceutical company founded in 2012 by Dr. Ke Wu and Mr. Jin Shi, specializing in the research, development, manufacturing, and marketing of human vaccines. Dr. Wu, the CEO and Chairman, holds a PhD in Immunology and has over 30 years of experience in the biotechnology industry, having successfully developed seven biological products approved by the NMPA. Mr. Shi, the Vice President, has three decades of experience in the biological products industry, with extensive expertise in quality control and management.

The company's business model is focused on the industrialization of its vaccine pipeline to serve both domestic Chinese and global markets. BravoVax aims to provide safe, effective, and affordable vaccines, with a particular focus on the needs of developing countries. Its operations are guided by cGMP standards from the NMPA, WHO, and EMA. The company has established multiple technology platforms, including those for polysaccharide-protein conjugate vaccines, adenovirus vectors, attenuated and inactivated vaccines, and recombinant proteins. Its pipeline includes a next-generation Pneumococcal Conjugate Vaccine (PCV), a multivalent Rotavirus Vaccine, a broad-spectrum Human Papillomavirus (HPV) Vaccine, a Recombinant Varicella-zoster Virus (HZV) Vaccine, and a Respiratory Syncytial Virus (RSV) vaccine.

BravoVax actively forms strategic partnerships to advance its research and development. It has entered into collaborations with international bodies like the U.S. National Institutes of Health (NIH) and Johns Hopkins University for a next-generation HPV vaccine. In 2020, the company partnered with GeoVax Labs to co-develop a COVID-19 vaccine candidate. Recognized as a "state-level high-tech enterprise," BravoVax has received honors such as being named a "Gazelle Enterprise" and is part of the "3551 Optics Valley Talent Programme."

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
12.4/100

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2021 $28M $110M Zhejiang Yatai Pharmaceutical · GF Venture Capital · Shifeng Xinhui · Beizeng Assets ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Wuhan Bowo Biological Technology website traffic

Latest recorded traffic for Wuhan Bowo Biological Technology is 940 monthly website visits, up 291.7% over the last three months.

Latest monthly visits940 3-month web change+291.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Wuhan Bowo Biological Technology in the Wuhan ecosystem

Live from Dealroom

The Wuhan Bowo Biological Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Zhejiang Yatai Pharmaceutical
  • GF Venture Capital
  • Shifeng Xinhui
  • Beizeng Assets
  • Chengda University
Employees 16 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Wuhan Bowo Biological Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Wuhan Bowo Biological Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.